Clinical trial
BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic…
NCT00040989 · Jonsson Comprehensive Cancer Center, Other · Withdrawn
Key facts
| NCT number | NCT00040989 |
|---|---|
| Title | BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer |
| Official title | Phase II Study of BAY 56-3722 in Patients With Recurrent, Unresectable, or Metastatic Renal Cell Carcinoma |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer |
| Intervention type | Drug, Procedure |
| Interventions | BAY 56-3722, enzyme inhibitor therapy |
| Enrollment | 0 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 10, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: